Human Papillomavirus (HPV)

Immunization coverage

Key facts
 
  • Immunization prevents illness, disability and death from vaccine-preventable diseases including cervical cancer, diphtheria, hepatitis B, measles, mumps, pertussis, pneumonia, polio, rotavirus diarrhoea, rubella and tetanus.
  • Global vaccination coverage is holding steady.
  • Immunization currently averts an estimated 2 to 3 million deaths every year.
  • But an estimated 21.8 million infants worldwide are still missing out on basic vaccines.
 
Overview
 
Undefined

Takeda transfers HPV vaccine rights as it continues globalization push

Takeda has been singing a globalization mantra when it comes to its vaccines unit, and that's already led it to dump one R&D program as it zeroes in on "higher impact" public health endeavors. Now, it's bowing out of another vaccine program--this time for HPV.
 
Undefined

CDC advisory panel recommends HPV vaccine

The Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention (CDC) added GARDASIL 9 to its list of recommended HPV vaccines, the nine-valent HPV vaccine’s maker Merck said on Thursday.
 
The recommendations call for females between the ages of 9 and 26 and males between the ages of 9 and 21 receive the vaccine.
 
The CDC committee especially recommends the vaccine for people who have not yet received any HPV vaccine or finished the 3 doses.
 
Undefined

Serum Institute gets Genticel's Vaxiclase tech to develop pertussis vaccine

With recent news of clinical trials for its low-cost HPV vaccine, the Serum Institute made waves in the world of Big Pharma. The India-based vaccinemaker--which is also working on other low-cost vaccines, such as a powdered measles vaccine--is now gearing up to challenge the world's leading vaccinemakers in another area: pertussis.
 
Undefined

FDA approves latest Gardasil HPV vaccine

The Food and Drug Administration recently approved Gardasil 9, which guards against nine strains of the human papillomavirus (HPV).
 
Several recent clinical trials indicate that Gardasil 9 is 97 percent effective in preventing people from contracting vaginal, vulvar and cervical cancers.
 
One of the studies included 13,000 subjects. The most common side effects included pain at the injection site, headaches, redness and swelling. The FDA has approved the vaccine for females ages 9-25 years old and males 9-15 years old.
 
Undefined

Newest HPV Vaccine Protects Against 9 Strains

A vaccine to prevent five additional strains of human papillomavirus (HPV) than the current quadrivalent (4-strain) HPV vaccine was approved yesterday by Food and Drug Administration.
 
Gardasil 9, manufactured by Merck Sharp & Dohme Corp, was approved for females aged 9 to 26 and males aged 9 to 15. The additional strains according to the FDA, can potentially prevent up to 90 percent of cervical, vulvar, vaginal and anal cancers.
 
Undefined

Merck wins FDA approval for Gardasil follow-up

Merck's ($MRK) Gardasil follow-up is here, meaning blockbuster sales figures are likely on the way. But the bad news is that they'll come at the expense of the world's second-best-selling shot.
 
On Wednesday, the FDA approved Gardasil 9, which prevents cervical, vulvar, vaginal and anal cancers caused by the four HPV types its predecessor protects against, as well as an additional 5 types--31, 33, 45, 52 and 58--that cause approximately one-fifth of cervical cancers, according to the FDA.
 
Undefined

University of Buffalo Develops new transport System for DNA Vaccines for HIV, Malaria, HPV, and Other Major Illnesses

Its performance isn’t measured by the distance it travels, but rather the delivery of its cargo: vaccines that contain genetically engineered DNA to fight HIV, cancer, influenza and other maladies.
 
Described recently in the Proceedings of the National Academy of Sciences, the technology is a biomedical advancement that could help unleash the potential of DNA vaccines, which despite two decades of research, have yet to make a significant impact in the treatment of major illnesses.
 
Undefined

Free HPV vaccination program sees upward trend in those vaccinated

The launch of a temporary free-of-charge human papillomavirus (HPV) vaccination program in Europe was well accepted and showed an increase in the percentage of those that took action and got the HPV vaccine from 17 percent to a 75 percent.
 
The increase was most notable among descendants and immigrants.
 
Undefined

Reseach shows hope for natural vaccines to control disease

Those infected with the herpes virus have new hope in controlling outbreaks and the research garnering them hope could also help others with other immune diseases, according to the Center for the Biology of Chronic Disease (CBCD).
 
Undefined

Pages